查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1830973

体外二氧化碳去除装置市场

Extracorporeal CO2 Removal Devices Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

体外二氧化碳去除装置市场预计将从 2024 年的 1.125 亿美元扩大到 2031 年的 1.8436 亿美元，预计 2025 年至 2031 年的复合年增长率为 6.4%。

市场洞察与分析师观点：慢性阻塞性肺病 (COPD) 盛行率的上升和老龄人口的增加推动了体外二氧化碳去除装置市场的成长。然而，有关体外二氧化碳去除装置的严格监管对市场成长构成了挑战。

体外二氧化碳去除装置因其安全性、有效性和可行性而获得认可。在临床应用中，建议用于呼吸支持，以帮助控制慢性阻塞性肺病 (COPD) 和急性呼吸窘迫症候群 (AHRS) 的恶化。众多製造商正致力于研发技术先进且创新的体外二氧化碳去除装置，以提升其市场占有率。此外，越来越多易患慢性阻塞性肺病 (COPD) 的老年患者正在使用体外二氧化碳去除装置来提高其存活率。因此，肺阻塞性疾病发生率的上升是促进体外二氧化碳去除装置市场规模扩张的重要因素。然而，使用这些装置也存在感染、低氧血症或因血流受限而导致的血栓形成等风险，这些风险可能导致严重的健康问题，并对市场成长构成长期挑战。

成长动力：慢性阻塞性肺病发病率上升推动体外二氧化碳去除装置市场发展2019 年疾病负担研究报告称，全球有 2.123 亿例 COPD 病例和 330 万例 COPD 相关死亡病例。空气污染加剧是导致 COPD 等呼吸系统疾病的重要因素。此外，经济合作暨发展组织 (OECD) 预测，到 2050 年全球温室气体排放量将增加约 50%，二氧化碳排放量将增加 70%。据估计，到 2050 年，大气中温室气体浓度可能达到 685 ppm 二氧化碳当量，可能导致平均气温比工业化前水平上升 3 至 6°C。

2021 年 1 月，发表在《PLoS ONE》杂誌上的一项研究表明，法国约有 260 万人患有 COPD，预计到 2025 年这一数字将增至 280 万人。根据美国国家健康科学 2022 年的资料，2020-21 年期间，英格兰约有 117 万人被诊断出患有 COPD，占总人口的 1.9%。世界卫生组织将 COPD 确定为全球第三大死因，2022 年造成约 320 万人死亡。此外，美国肺臟协会报告称，美国每年有超过 1,100 万人被诊断出患有 COPD。因此，人群中 COPD 的巨大负担推动了对体外二氧化碳去除装置的需求，以增强血液流动并促进有效的气体交换，从而推动体外二氧化碳去除装置市场的成长。

策略性洞察报告细分和范围：「体外二氧化碳去除装置市场分析」是透过检查以下细分进行的：产品、应用和最终用户。

細項分析：根据应用，体外二氧化碳移除装置市场分为急性呼吸窘迫症候群 (ARDS)、慢性阻塞性肺病 (CBP) 和其他疾病。慢性阻塞性肺病 (CBP) 领域在 2022 年占据了最大的市场。预计在预测期内，急性呼吸窘迫症候群 (ARDS) 领域的复合年增长率最高，为 7.7%。人们对 ARDS 及其早期发现的认识不断提高，导致患者诊断和治疗数量增加，从而导致对用于 ARDS 管理的体外二氧化碳去除装置的需求增加。因此，医疗保健提供者越来越有信心将体外二氧化碳去除装置整合到他们的 ARDS 治疗方案中。

体外二氧化碳移除装置有助于降低呼吸频率和潮气量，从而延长呼气时间，使其更符合呼吸系统的高呼气时间常数。英国肺臟协会估计，英国约有120万人被诊断出患有慢性阻塞性肺病 (COPD)。因此，COPD盛行率的上升预计将加速全球体外二氧化碳去除装置市场的发展。

依产品划分，体外二氧化碳去除装置市场分为体外二氧化碳去除装置和耗材。体外二氧化碳去除装置细分市场在2022年占据了更大的市场份额，而耗材细分市场预计在预测期内将实现更高的复合年增长率，达到7.6%。由于技术简化，体外二氧化碳去除装置所需的人员和物流更少，从而提高了患者的偏好。这使得体外二氧化碳去除装置细分市场得以维持其市场地位。

体外二氧化碳移除过程需要为每位患者提供一套全新的耗材，因此各种COPD和ARDS相关手术对耗材的需求很高。因此，预计体外二氧化碳去除装置耗材市场在预测期内将持续成长。

按最终用户划分，市场可细分为医院和诊所、门诊手术中心和其他。 2022年，医院和诊所占据了体外循环二氧化碳去除设备市场的最大份额，预计在预测期内将实现7.4%的最高复合年增长率。医院，尤其是配备专门加护病房 (ICU) 和呼吸科的医院，拥有救治重症患者的设备。此外，医院通常拥有由多学科医疗专业人员组成的团队，包括肺科医生、重症监护医生、呼吸治疗师和灌注师，他们通力合作，共同治疗有复杂呼吸需求的患者。这些专业知识对于安全有效地使用体外循环二氧化碳去除设备至关重要。

技术进步推动体外二氧化碳去除装置市场发展小型体外二氧化碳去除装置侵入性较小，可为患者提供更高的舒适度。它们通常需要更小的血管通路，从而降低了併发症的风险。由于患者不再受限于大型、无法移动的装置，他们可以享受更高的活动性和舒适度，从而提高整体治疗品质。膜技术的进步显着提高了体外二氧化碳去除装置的有效性和效率，使其能够选择性地扩散二氧化碳，同时保留红血球和蛋白质等重要血液成分。这种选择性降低了溶血和其他血液相关併发症的风险。

随着老年人口健康状况的下降，维持生活品质的需求日益增长，体外二氧化碳去除装置对于提供微创、更温和的呼吸支持至关重要。体外二氧化碳去除 (ECCO2R) 的技术创新催生了更用户友好且便携的设备。随着 ECCO2R 的益处日益得到认可，它正被纳入老年人的治疗计划中。因此，持续的技术进步可能会在未来几年为体外二氧化碳去除装置市场带来新的趋势。

区域分析：体外二氧化碳去除装置市场报告的范围包括北美、欧洲、亚太、南美和中美以及中东和非洲。

2022年，北美占据了体外二氧化碳去除设备市场的最大份额。该地区的成长得益于医疗基础设施的增强和体外二氧化碳去除设备的高普及率，尤其是在美国和加拿大新冠疫情期间。新技术的早期应用以及ARDS和COPD患者群体的庞大规模预计将进一步加速该地区的市场成长。此外，慢性呼吸系统疾病发生率的上升以及对安全、快速、微创呼吸器的偏好，预计也将在预测期内推动体外二氧化碳去除设备市场的成长。

预计欧洲将占据全球体外二氧化碳去除设备市场的第二大份额，这得益于该地区医疗设备需求的不断增长以及呼吸衰竭等慢性疾病的发病率不断上升。此外，优惠的报销政策、政府对长期医疗保健的投入增加以及医疗保健研究基础设施的增强，也有助于提高体外二氧化碳去除设备的利用率。

预计亚太地区体外二氧化碳去除装置市场在预测期内将达到7.3%的最快成长率。这一增长得益于庞大的患者群体、对急性呼吸衰竭认识的提高以及印度和日本等发展中国家政府医疗保健支出的增加。此外，跨国公司正在寻求在中国等发展中国家投资，从而推动该地区的市场成长。

体外二氧化碳去除装置市场报告范围：产业发展与未来机会：体外二氧化碳去除装置市场的预测可以帮助利害关係人规划其成长策略。以下是一些市场领导企业的策略发展：

2022年10月，ALung Technologies评估了Hemolung呼吸辅助系统（RAS）低流量体外二氧化碳去除（ECCO2R）的安全性和有效性，该系统作为有创机械通气的替代或辅助手段，适用于因慢性阻塞性肺病（COPD）急性加重而需要呼吸支持的患者。 2022年3月，美国呼吸健康技术公司Respira Labs推出了Sylvee，这是一款由人工智慧驱动的可穿戴肺监测器，利用声学共振来评估肺功能并检测肺容量波动。本设备可辅助检测和治疗慢性阻塞性肺病、气喘和新冠肺炎 (COVID-19)。 2021 年 5 月，ALung Technologies, Inc. 的下一代 Hemolung RAS 体外二氧化碳去除系统获得 FDA 批准，旨在为急性呼吸衰竭患者提供呼吸支持。 2020 年 5 月，ALung Technologies, Inc. 宣布下一代人工肺 Hemolung RAS 的商业化开发。竞争格局与重点公司：体外二氧化碳去除设备市场报告中介绍的重点公司包括 Getinge、ALung Technologies, Inc.、Estor、NovaLung GmbH、Hemodec、Baxter Healthcare、Eurosets、LivaNova、Medtronic 和 Xenios AG。这些公司专注于开发新技术、改进现有产品并扩大其地理覆盖范围，以满足日益增长的全球消费者需求。

目录

第一章：简介

第二章：执行摘要

  • 关键见解
  • 市场吸引力分析

第三章：研究方法

第四章：体外二氧化碳去除装置市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链中的供应商列表

第五章：体外二氧化碳去除装置市场－关键市场动态

  • 关键市场驱动因素
  • 主要市场限制因素
  • 关键市场机会
  • 未来趋势
  • 驱动因素和限制因素的影响分析

第六章：体外二氧化碳去除装置市场－全球市场分析

  • 体外二氧化碳去除装置－全球市场概览
  • 体外二氧化碳去除装置－全球市场及2030年预测

第七章：体外二氧化碳去除装置市场-收入分析-依产品，2020-2030

  • 概述
  • 体外二氧化碳装置
  • 耗材

第 8 章：体外二氧化碳移除装置市场 - 收入分析 - 按应用，2020-2030 年

  • 概述
  • 慢性阻塞性肺臟疾病
  • 急性呼吸窘迫症候群
  • 其他的

第九章：体外二氧化碳移除装置市场-收入分析-依最终用户，2020-2030

  • 概述
  • 医院和诊所
  • 门诊手术中心
  • 其他的

第 10 章：体外二氧化碳移除装置市场 - 收入分析，2020-2030 年 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 11 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 12 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第 13 章：体外二氧化碳移除装置市场 - 主要公司简介

  • Getinge AB
  • ALung Technologies, Inc.
  • Xenios AG
  • Estor SpA
  • Medtronic
  • Hemodec
  • NovaLung GmbH
  • Baxter Healthcare
  • Eurosets
  • LivaNova

第 14 章：附录

简介目录
Product Code: TIPMD00002259

The extracorporeal CO2 removal devices market is anticipated to expand from US$ 112.5 million in 2024 to US$ 184.36 million by 2031, with a projected CAGR of 6.4% from 2025 to 2031.

Market Insights and Analyst Perspective:The growth of the extracorporeal CO2 removal devices market is driven by the rising prevalence of chronic obstructive pulmonary diseases (COPD) and an increasing elderly population. However, stringent regulations concerning extracorporeal CO2 removal devices pose challenges to market growth.

Extracorporeal CO2 removal devices are recognized for their safety, effectiveness, and feasibility. Their application in ventilatory support is recommended in clinical scenarios where they can help manage exacerbations of COPD and acute respiratory distress syndrome. Numerous manufacturers are concentrating on creating technologically advanced and innovative extracorporeal CO2 removal devices to enhance their market presence. Additionally, a growing number of elderly patients susceptible to COPD are being connected to extracorporeal CO2 removal devices to boost their survival rates. Consequently, the rising incidence of pulmonary obstructive diseases is a significant factor contributing to the expansion of the extracorporeal CO2 removal devices market size. Conversely, the use of these devices carries risks such as infection, hypoxemia, or thrombosis due to restricted blood flow, which can lead to severe health issues and present a long-term challenge to market growth.

Growth Drivers:Rising Incidence of Chronic Obstructive Pulmonary Diseases Fuels Extracorporeal CO2 Removal Devices Market

The Burden of Disease Study in 2019 reported 212.3 million cases of COPD and 3.3 million COPD-related deaths worldwide. A significant contributor to respiratory diseases like COPD is the increasing air pollution. Furthermore, the Organization for Economic Co-operation and Development (OECD) predicts that global greenhouse gas emissions will rise by approximately 50% by 2050, with CO2 emissions increasing by 70%. It is also estimated that atmospheric concentrations of greenhouse gases could reach 685 parts per million (ppm) CO2 equivalent by 2050, potentially causing average temperatures to rise by 3 to 6°C above pre-industrial levels.

In January 2021, a study published in the journal PLoS ONE indicated that around 2.6 million individuals in France were affected by COPD, with projections suggesting this number will increase to 2.8 million by 2025. According to 2022 data from National Health Science, approximately 1.17 million people were diagnosed with COPD in England during 2020-21, accounting for 1.9% of the total population. The WHO identifies COPD as the third leading cause of death globally, resulting in about 3.2 million deaths in 2022. Additionally, the American Lung Association reports that over 11 million people in the US are diagnosed with COPD annually. Thus, the substantial burden of COPD within the population drives the demand for extracorporeal CO2 removal devices to enhance blood flow and facilitate efficient gas exchange, thereby propelling the growth of the extracorporeal CO2 removal devices market.

Strategic Insights

Report Segmentation and Scope:The "extracorporeal CO2 removal devices market analysis" has been conducted by examining the following segments: product, application, and end user.

Segmental Analysis:In terms of application, the extracorporeal CO2 removal devices market is divided into acute respiratory distress syndrome, chronic obstructive pulmonary disease, and others. The chronic obstructive pulmonary disease segment accounted for the largest market share in 2022. The acute respiratory distress syndrome segment is expected to exhibit the highest CAGR of 7.7% during the forecast period. Growing awareness of ARDS and its early detection has led to an increase in patient diagnoses and treatments, resulting in heightened demand for extracorporeal CO2 removal devices designed for ARDS management. Consequently, healthcare providers are increasingly confident in integrating extracorporeal CO2 removal devices into their ARDS treatment protocols.

Extracorporeal CO2 removal devices facilitate a reduction in respiratory rate and tidal volume, leading to an extended expiratory time that aligns better with the respiratory system's high expiratory time constant. The British Lung Association estimates that around 1.2 million individuals in the UK are living with diagnosed COPD. Therefore, the rising prevalence of COPD is expected to accelerate the global extracorporeal CO2 removal devices market.

By product, the extracorporeal CO2 removal devices market is categorized into extracorporeal CO2 devices and consumables. The extracorporeal CO2 devices segment held a larger market share in 2022, while the consumables segment is projected to achieve a higher CAGR of 7.6% during the forecast period. Due to technical simplifications, extracorporeal CO2 removal devices require fewer personnel and logistics, enhancing patient preference. This has allowed the extracorporeal CO2 removal devices segment to maintain its market position.

The process of extracorporeal CO2 removal necessitates a fresh set of consumables for each patient, resulting in a high demand for consumables in various COPD and ARDS-related procedures. Thus, the market for the consumables segment of extracorporeal CO2 removal devices is expected to continue its growth during the forecast period.

By end user, the market is segmented into hospitals and clinics, ambulatory surgical centers, and others. The hospitals and clinics segment captured the largest share of the extracorporeal CO2 removal devices market in 2022 and is expected to register the highest CAGR of 7.4% during the forecast period. Hospitals, particularly those with specialized intensive care units (ICUs) and respiratory facilities, are equipped to care for the most critically ill patients. Moreover, hospitals typically have multidisciplinary teams of healthcare professionals, including pulmonologists, critical care physicians, respiratory therapists, and perfusionists, who collaborate to treat patients with complex respiratory needs. This expertise is crucial for the safe and effective use of ECCO2R devices.

Technological Advancements to Propel Extracorporeal CO2 Removal Devices Market

Smaller extracorporeal CO2 removal devices are less invasive and provide greater comfort for patients. They often require smaller vascular access, which reduces the risk of complications. As patients are not confined to large, immobile devices, they can enjoy increased mobility and comfort, enhancing the overall quality of treatment. Advances in membrane technology have significantly improved the effectiveness and efficiency of extracorporeal CO2 removal devices, allowing selective diffusion of CO2 while preserving essential blood components such as red blood cells and proteins. This selectivity reduces the risk of hemolysis and other blood-related complications.

With the growing need to maintain quality of life in the aging population due to their declining health conditions, extracorporeal CO2 removal devices are vital in providing less invasive and gentler respiratory support. Technological innovations in extracorporeal CO2 removal (ECCO2R) have led to the creation of more user-friendly and portable devices. As the benefits of ECCO2R become increasingly recognized, it is being integrated into treatment plans for older adults. Therefore, ongoing technological advancements are likely to introduce new trends in the extracorporeal CO2 removal devices market in the coming years.

Regional Analysis:The scope of the extracorporeal CO2 removal devices market report includes North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

In 2022, North America held the largest share of the extracorporeal CO2 removal devices market. The growth in this region is attributed to enhanced healthcare infrastructure and a high adoption rate of extracorporeal CO2 removal devices, particularly during the COVID-19 pandemic in the US and Canada. The early adoption of new technologies and a large patient population for ARDS and COPD are expected to further accelerate market growth in the region. The rising incidence of chronic respiratory diseases and a preference for safe, rapid, minimally invasive ventilators are also anticipated to boost the growth of the extracorporeal CO2 removal devices market during the forecast period.

Europe is expected to hold the second-largest share of the global extracorporeal CO2 removal devices market, driven by increasing demand for healthcare devices and a rising prevalence of chronic diseases such as respiratory failure in the region. Additionally, favorable reimbursement policies, increased government investments in long-term healthcare, and enhanced healthcare research infrastructures are contributing to higher utilization rates of extracorporeal CO2 removal devices.

The extracorporeal CO2 removal devices market in the Asia Pacific region is projected to experience the fastest growth rate of 7.3% during the forecast period. This growth is fueled by a large patient population, heightened awareness of acute respiratory failure, and increased government healthcare spending in developing countries like India and Japan. Furthermore, multinational companies are looking to invest in developing countries such as China, thereby promoting market growth in the region.

Extracorporeal CO2 Removal Devices Market Report Scope

Industry Developments and Future Opportunities:The forecast for the extracorporeal CO2 removal devices market can assist stakeholders in planning their growth strategies. Below are some strategic developments by leading players in the market:

In October 2022, ALung Technologies assessed the safety and effectiveness of the hemolung respiratory assist system (RAS) for low-flow extracorporeal CO2 removal (ECCO2R) as an alternative or adjunct to invasive mechanical ventilation for patients needing respiratory support due to acute exacerbations of chronic obstructive pulmonary disease (COPD).

In March 2022, Respira Labs, a US-based respiratory health technology firm, launched Sylvee, an AI-powered wearable lung monitor that utilizes acoustic resonance to evaluate lung function and detect fluctuations in lung volume. This device can aid in the detection and treatment of chronic obstructive pulmonary disease, asthma, and COVID-19.

In May 2021, ALung Technologies, Inc. received FDA clearance for its next-generation Hemolung RAS extracorporeal CO2 removal system, designed to provide respiratory support to patients experiencing acute respiratory failure.

In May 2020, ALung Technologies, Inc. announced the commercial development of the next-generation artificial lung known as the hemolung RAS.

Competitive Landscape and Key Companies:Key companies profiled in the extracorporeal CO2 removal devices market report include Getinge, ALung Technologies, Inc., Estor, NovaLung GmbH, Hemodec, Baxter Healthcare, Eurosets, LivaNova, Medtronic, and Xenios AG. These companies are focused on developing new technologies, enhancing existing products, and expanding their geographic reach to meet the growing global consumer demand.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Extracorporeal CO2 Removal Devices Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Extracorporeal CO2 Removal Devices Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Extracorporeal CO2 Removal Devices Market - Global Market Analysis

  • 6.1 Extracorporeal CO2 Removal Devices - Global Market Overview
  • 6.2 Extracorporeal CO2 Removal Devices - Global Market and Forecast to 2030

7. Extracorporeal CO2 Removal Devices Market - Revenue Analysis (USD Million) - By Product, 2020-2030

  • 7.1 Overview
  • 7.2 Extracorporeal CO2 Devices
  • 7.3 Consumables

8. Extracorporeal CO2 Removal Devices Market - Revenue Analysis (USD Million) - By Application, 2020-2030

  • 8.1 Overview
  • 8.2 Chronic Obstructive Pulmonary Disease
  • 8.3 Acute Respiratory Distress Syndrome
  • 8.4 Others

9. Extracorporeal CO2 Removal Devices Market - Revenue Analysis (USD Million) - By End User, 2020-2030

  • 9.1 Overview
  • 9.2 Hospitals and Clinics
  • 9.3 Ambulatory Surgical Centers
  • 9.4 Others

10. Extracorporeal CO2 Removal Devices Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Extracorporeal CO2 Removal Devices Market Overview
    • 10.1.2 North America Extracorporeal CO2 Removal Devices Market Revenue and Forecasts to 2030
    • 10.1.3 North America Extracorporeal CO2 Removal Devices Market Revenue and Forecasts and Analysis - By Product
    • 10.1.4 North America Extracorporeal CO2 Removal Devices Market Revenue and Forecasts and Analysis - By Application
    • 10.1.5 North America Extracorporeal CO2 Removal Devices Market Revenue and Forecasts and Analysis - By End User
    • 10.1.6 North America Extracorporeal CO2 Removal Devices Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Extracorporeal CO2 Removal Devices Market
        • 10.1.6.1.1 United States Extracorporeal CO2 Removal Devices Market, by Product
        • 10.1.6.1.2 United States Extracorporeal CO2 Removal Devices Market, by Application
        • 10.1.6.1.3 United States Extracorporeal CO2 Removal Devices Market, by End User
      • 10.1.6.2 Canada Extracorporeal CO2 Removal Devices Market
        • 10.1.6.2.1 Canada Extracorporeal CO2 Removal Devices Market, by Product
        • 10.1.6.2.2 Canada Extracorporeal CO2 Removal Devices Market, by Application
        • 10.1.6.2.3 Canada Extracorporeal CO2 Removal Devices Market, by End User
      • 10.1.6.3 Mexico Extracorporeal CO2 Removal Devices Market
        • 10.1.6.3.1 Mexico Extracorporeal CO2 Removal Devices Market, by Product
        • 10.1.6.3.2 Mexico Extracorporeal CO2 Removal Devices Market, by Application
        • 10.1.6.3.3 Mexico Extracorporeal CO2 Removal Devices Market, by End User
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Extracorporeal CO2 Removal Devices Market - Key Company Profiles

  • 13.1 Getinge AB
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 ALung Technologies, Inc.
  • 13.3 Xenios AG
  • 13.4 Estor SpA
  • 13.5 Medtronic
  • 13.6 Hemodec
  • 13.7 NovaLung GmbH
  • 13.8 Baxter Healthcare
  • 13.9 Eurosets
  • 13.10 LivaNova

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud